Overview

A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension

Status:
Completed
Trial end date:
2009-08-12
Target enrollment:
Participant gender:
Summary
This study determined the maximum dose of LCI6999 with respect to effect on the ACTH-stimulated cortisol response in participants with hypertension.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Collaborators:
Great Lakes Drug Development, Inc.
Integrium
Treatments:
Cortisol succinate
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate